Ex vivo production of neutrophils. Relentless infections frequently occur in patients receiving intensive chemotherapy treatment. Chemotherapy is toxic to the bone marrow where blood cells are produced. A low white blood cell count and in particular a low neutrophil count is linked with infection in these patients. Unlike red cells and platelets, neutrophils are difficult to collect from blood donors and hence are not routinely available. In this project, we will develop a practical, cost effic ....Ex vivo production of neutrophils. Relentless infections frequently occur in patients receiving intensive chemotherapy treatment. Chemotherapy is toxic to the bone marrow where blood cells are produced. A low white blood cell count and in particular a low neutrophil count is linked with infection in these patients. Unlike red cells and platelets, neutrophils are difficult to collect from blood donors and hence are not routinely available. In this project, we will develop a practical, cost efficient process for the production of neutrophils from cord blood. Transfusion of these neutrophils should reduce the chance of patients suffering serious infection, allow them to recover faster from their chemotherapy, and reduce the need for admission to intensive care.Read moreRead less
EX VIVO PRODUCTION OF MATURE RED BLOOD CELLS FOR TRANSFUSION. This project aims to establish a practical, cost efficient biotechnology platform for the expansion and maturation of blood stem cells to produce blood transfusion products. Red blood cell production will be used as the prototype model. It is envisaged that blood bioreactors will initially supplement and ultimately replace the current blood donor based process, thus overcoming the on-going donor recruitment, retention and safety issue ....EX VIVO PRODUCTION OF MATURE RED BLOOD CELLS FOR TRANSFUSION. This project aims to establish a practical, cost efficient biotechnology platform for the expansion and maturation of blood stem cells to produce blood transfusion products. Red blood cell production will be used as the prototype model. It is envisaged that blood bioreactors will initially supplement and ultimately replace the current blood donor based process, thus overcoming the on-going donor recruitment, retention and safety issues associated with collection of single units of blood. This project is focused on providing solutions to two key technical and economical challenges: (a) achieving full maturation of red blood cells and (b) achieving at least a 100-fold intensification of the expansion and maturation process through perfusion.Read moreRead less